This is the Drug That Could Kick Regeneron's Stock Into Gear Post author:Sam Post published:December 13, 2017 Post category:BioPharma Regeneron shares have made little headway since the disappointing launch of Praluent in 2015. Source: BioSpace You Might Also Like Generation Bio Raises $100 Million Series B to Finance Non-Viral Gene Therapy Program February 26, 2018 Creative Bioarray Release: New Products of FISH Have Been Released In Company January 19, 2017 Ironwood To Host Second Quarter 2017 Investor Update Call July 20, 2017
Generation Bio Raises $100 Million Series B to Finance Non-Viral Gene Therapy Program February 26, 2018